Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00714961 · ClinicalTrials.gov registry record · Phase 3
Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,491
- Enrollment target
NCT00714961 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 3,491 participants.
The verdict
NCT00714961, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,491 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart attack that was treated with fibrinolytic therapy.
Interventions
- DRUG Placebo
- DRUG Clopidogrel (SR25990)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,491 participants |
| Start Date | 2003-02 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00714961
The ClinicalTrials.gov registry entry for NCT00714961 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,491 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00714961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00714961 about?
NCT00714961 is a clinical study titled "Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction". The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart attack that was treated with fibrinolytic therapy.
What is the current status of trial NCT00714961?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,491 participants. The study started on 2003-02. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00714961?
The interventions under investigation include: Placebo (DRUG), Clopidogrel (SR25990) (DRUG).
Who is sponsoring clinical trial NCT00714961?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.